US Patent

US7452882 — Thyroid hormone analogs

Composition of Matter · Assigned to Hoffmann La Roche Inc · Expires 2026-09-12 · 0y remaining

Vulnerability score 35/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects compounds of the formula (I) and their pharmaceutically acceptable salts, which are useful for treating various diseases including obesity and diabetes.

USPTO Abstract

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.

Drugs covered by this patent

Patent Metadata

Patent number
US7452882
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-09-12
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Hoffmann La Roche Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.